Company Announcement
No. 14/2010
30 December 2010
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN
Stabilization period has expired
Zealand Pharma A/S (the "Company") announces that the stabilization period following the Company’s initial public offering described in the prospectus dated 3 November 2010 as amended by prospectus supplement no. 1 dated 18 November 2010 and prospectus supplement no. 2 dated 19 November 2010 (the "Prospectus") (the "IPO") has expired.
On behalf of the Managers (as defined in the Prospectus) Danske Markets (Division of Danske Bank A/S) has acted as stabilizing agent in connection with the IPO and has informed the Company that the below mentioned stabilization transactions have been carried out in the shares of the Company during the stabilization period.
The stabilization started on 23 November2010 and stabilization last occurred on 23 December 2010. Stabilization transactions have been carried out in the following intervals:
DKK 76 - 85 from 23 to 24 November 2010
DKK 76 - 77 from 26 to 29 November 2010
DKK 76 - 78 from 7 to 8 December 2010
DKK 66.50 - 71.50 from 15 to 23 December 2010
# # #
For further information, please contact:
Zealand Pharma A/S
David Solomon, President and Chief Executive Officer
Tel: +45 4328 1200
M:Communications
Mary-Jane Elliott / Emma Thompson / Amber Bielecka
Tel: +44(0) 20 7920 2330
About Zealand Pharma A/S
Zealand Pharma is a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs. The Company targets diseases where it believes existing treatments fail to adequately serve the medical needs of patients and the market potential for improved treatments through the use of peptide drugs is high.
Zealand Pharma focuses on three therapeutic areas: metabolic (diabetes and obesity), gastrointestinal and cardiovascular diseases. The Company’s expertise in peptide discovery, optimization and development has resulted in a strong and growing pipeline of novel peptide drug candidates with favourable therapeutic attributes.
Since 1999, Zealand Pharma’s scientists have built a pipeline that includes five compounds in clinical development, four of which have been out licensed, two of these with major pharmaceutical companies (sanofi-aventis and Helsinn Healthcare). All of Zealand Pharma’s compounds emerged from the Company’s own drug discovery.
Zealand Pharma is based in Copenhagen. For more information please visit the Company’s web site: www.zealandpharma.com.
Disclaimer: This document does not contain or constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities in the United States or in any other jurisdiction.
This document is not an offer of securities for sale in the United States. The securities of Zealand Pharma A/S may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that will contain detailed information about the Company and management, as well as financial statements. Zealand Pharma A/S does not intend to conduct a public offering in the United States.
